Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)

Head and Neck Cancer Clinical Trial

Official title:

Phase II Study of RT Concurrent w/ Cetuximab in Patients w/ Locally Advanced Head & Neck SCC Who Do Not Qualify For Standard Chemotherapy Due To Age >70 Or Co-Morbidities

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00904345
• Other study ID #: UMCC 2009.009
• Secondary ID: HUM 27253
• Status: Terminated
• Phase: Phase 2
• Start date: April 2009
• Est. completion date: December 2020

Study information

• Verified date: February 2021
• Source: University of Michigan Rogel Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-arm, phase II trial to characterize the clinical outcome of standard of care, cetuximab concurrent with radiation, in a special population (head and neck cancer patients who cannot tolerate concurrent chemoradiotherapy due to advanced age, poor performance status or concurrent illness), and to determine if biomarker response to a loading dose of cetuximab is predictive of that outcome.

Description:

Primary Objective 1: Determine changes in tumor EGFR, pEGFR, downstream signaling and novel phosphoproteins following a loading dose of cetuximab in patients who are poor candidates for chemoradiation (age =70 years or with significant co-morbidities) and are therefore treated with cetuximab with radiation.

Primary Objective 2: Characterize clinical outcomes, including local recurrence, progression-free survival and overall survival in these patients, and correlate these clinical outcomes with the changes in tumor EGFR, pEGFR, downstream signaling, and novel phosphoproteins.

Primary Objective 3: Describe the toxicity, in particular mucositis/dysphagia, of this regimen.

Secondary Objective 1: Conduct normal mucosa EGFR assessment for comparison with tumor sample.

Secondary Objective 2: Correlate HPV presence and titer with p53 status and clinical outcome.

Other known NCT identifiers

• NCT01250522

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 23
• Est. completion date: December 2020
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

• Patients must have pathologically-confirmed, previously untreated, clinically accessible (without general anesthesia) locally advanced squamous cell carcinoma of the larynx, hypopharynx, oropharynx, oral cavity, or nonresectable head and neck squamous cell carcinomas of the skin.

• Patients will be limited to:

• = 70 years of age, OR

• with co-morbidities that preclude treatment with standard platinum-based chemotherapy, as determined by the treating physician, OR

• KPS = 80, OR

• Creatinine clearance < 30 cc/min

• Laboratory criteria:

• WBC > 3500/ul

• Granulocyte > 1500/ul

• Platelet count > 100,000/ul

• Total Bilirubin < 1.5 X ULN

• AST and ALT < 2.5 X ULN

• Patients must give documented informed consent to participate in this study.

Exclusion Criteria:

• Prior head and neck malignancy, or history of other prior non-head and neck malignancy within the past 3 years (excluding skin cancer and early stage treated prostate cancer).

• Prior head and neck radiation or chemotherapy.

• Documented evidence of distant metastases.

• Patients with nasopharyngeal carcinoma.

• Any medical or psychiatric illness, which, in the opinion of the principal investigator, would compromise the patient's ability to tolerate this treatment.

• Patients with psychiatric/social situations that would limit compliance with study requirements are not eligible.

• Patients with prior anti-epidermal growth-factor receptor antibody therapy (antibody or small molecule).

• Patients residing in prison.

Related Conditions & MeSH terms

• Head and Neck Cancer
• Head and Neck Neoplasms

Intervention

Drug:
• Cetuximab
Patients will receive a single dose of cetuximab 400 mg/m (Day 0). On day 7 (+/- 1 day), a repeat biopsy will be performed. Radiation concurrent with weekly cetuximab 250 mg/m.

Radiation:
• 50-60 Gy and 70 Gy
Within approximately 4 days (after single dose of Cetuximab), definitive radiation will begin (70 Gy in 35 fractions to the gross tumor, 50-60 Gy to subclinical target volumes) concurrent with weekly cetuximab 250 mg/m.

Locations

Country	Name	City	State
United States	University of Michigan Medical Center	Ann Arbor	Michigan
United States	University of Michigan Veterans Administration Hospital	Ann Arbor	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
University of Michigan Rogel Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Change in Tumor Epidermal Growth Factor Receptor (EGFR)	The ratio (fold change) of tumor EGFR post-loading dose/pre-loading dose of cetuximab. Reported as the mean of fold changes across all participants who had an evaluable tumor sample.	At baseline (pre-loading dose) and day 7 post-loading dose
Primary	Mean Change in Tumor Phosphorylated EGFR (pEGFR)	The ratio (fold change) of tumor pEGFR post-loading dose/pre-loading dose of cetuximab. Reported as the mean of fold changes across all participants who had an evaluable tumor sample.	At baseline (pre-loading dose) and day 7 post-loading dose
Primary	Progression Free Survival Rate	Percentage of participants who survived without recurrent disease, from the time of enrollment to 1 and 2 years.	At 1 and 2 years
Primary	Overall Survival Rate	Percentage of participants alive at 1 and 2 years after enrollment.	At 1 and 2 Years
Primary	Number of Participants With Treatment Related Toxicities	Toxicities are measured by number of participants who experience one or more types or indicator of toxicity, shown as all grades and grades 3-4. As each participant could have multiple toxicities, the total number of incidents outnumbers the number of participants. Toxicities are graded according to the CTCAE v4.	3 years
Secondary	Change in Tumor EGFR Level Relative to EGFR in Normal Mucosa	Normal mucosa EGFR was assessed for comparison with EGFR in tumor sample. The fold change in tumor EGFR level at post-loading dose/pre-loading dose of cetuximab, relative to fold change in normal mucosa EGFR level post-loading dose/pre-loading dose of cetuximab was summarized across all participants who had an evaluable tumor sample and normal mucosa sample. The value reported is the ratio of fold change in tumor/fold change in buccal EGFR.	At baseline (pre-loading dose) and day 7 post-loading dose
Secondary	Change in Tumor pEGFR Level Relative to pEGFR in Normal Mucosa	Normal mucosa pEGFR was assessed for comparison with pEGFR in tumor sample. The fold change in tumor pEGFR level post-loading dose/pre loading dose of cetuximab, relative to fold change in normal mucosa pEGFR level post-loading dose/pre-loading dose of cetuximab was summarized across all participants who had an evaluable tumor sample and normal mucosa sample. The value reported is the ratio of fold change in tumor/fold change in buccal pEGFR.	At baseline (pre-loading dose) and day 7 post-loading dose